All In Biotech

Drug Trial Radar · NCT06914713

Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF

Efficacy Evaluation of Jin-shui Huan-xian Formula in Retarding the Decline of Pulmonary Function in IPF

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 384 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

384

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

Dec 30, 2027

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Henan University of Traditional Chinese MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui Huan-xian Formula for retarding the decline of pulmonary function in Idiopathic Pulmonary Fibrosis(IPF)

Conditions

  • Idiopathic Pulmonary Fibrosis(IPF)

Interventions

  • Jin-shui Huan-xian granuleDrug

    Jin-shui Huan-xian Granules: on the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Jin-shui Huan-xian Granules for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.

  • Jin-shui Huan-xian granule placeboDrug

    Jin-shui Huan-xian granule placebo: on the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Jin-shui Huan-xian Granules placebo for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.The Jin-shui Huan-xian granules and their placebo are identical in appearance, weight, color and smell.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced vital capacity (FVC)Time frame: The change in absolute FVC value before treatment and at 52 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Affiliated Hospital of Henan University of Chinese Medicine

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.